Sun Pharma Eye Drops Recall: Company Stops Distribution of Lotepred, Brinolar, and Other Products

Sun Pharma Distributors Ltd has issued a withdrawal notice for several eye drop products as a precautionary measure, asking distributors to stop billing and return existing stocks. The company’s confidential letter dated July 17 listed multiple products, including Lotepred, Brinolar and other eye drops, for withdrawal from distribution channels.

The company informed distributors that further distribution of the listed products should be discontinued immediately and requested details of available stock. Sun Pharma said the decision was taken in the interest of patient safety and in accordance with regulatory requirements. Pepsi, Red Bull and Others Ordered To Remove 'Energy Drink' Labels in India by FSSAI; Here's Why.

Sun Pharma Issues Distributor Alert

According to a copy of the letter accessed by ANI, Sun Pharma Distributors Ltd instructed distributors to stop selling the affected products and return all available stocks.

The notice stated: “Withdrawal of Product - Depopred2ML, Brinolar (BKC FREE), Brinzotim Eye Drops 5ML BKC FREE, Lotepred-5ML, Lotepred 1% Eye Drops SML, Lotepred LS 0.2%E/D5ML, Lotepred T, Nepalact OD Eye Drops 3ML, Nepalact-Z, Toba-F & Nepalact E/D 5ML.” What Is QDENGA and How Does It Work? All About India's First Dengue Vaccine.

The company further informed distributors: “Sun Pharma Distributors Ltd has decided, as a precautionary measure, to discontinue further distribution and withdraw of all existing stocks of the above products available in your channel.”

Distributors Asked to Stop Billing and Return Stocks

Sun Pharma requested distributors to immediately stop billing the listed products and share details of any remaining inventory.

The company said: “In this regard, you are requested to immediately cease billing of the above-mentioned product and provide us details of any stock currently held by you. Further, you are requested to send back to us any stocks of the product available with you as well as those received from any sources on priority.” The notice did not specify the exact reason behind the withdrawal.

Sun Pharma Says Patient Safety Is Priority

Responding to ANI, a Sun Pharma spokesperson said the company had taken necessary measures to protect patients.

The spokesperson said: “Patient safety remains our highest priority. We have taken all necessary steps in the best interest of patients and in accordance with applicable regulatory requirements. Our teams are working diligently to restore the availability of these products so that patients continue to have access to these treatment options.”

A medical expert said several of the recalled eye drops are commonly prescribed for conditions including recovery after eye surgeries, glaucoma management, infections, allergies and eye inflammation.

The expert said: “Many of these eye drops are prescribed for patients recovering from eye surgery or managing chronic conditions such as glaucoma, eye infections, allergies, and ocular inflammation, where interruption of treatment can have significant consequences. In a country like India, where millions rely on eye drops every day, maintaining sterility during manufacturing is non-negotiable. Even suspected contamination at a manufacturing facility can pose a serious risk to patient safety, making immediate product recalls essential. Patients should not continue using a recalled product or discontinue treatment on their own, but should contact their ophthalmologist promptly so that an appropriate alternative can be prescribed, ensuring continuity of care while safeguarding vision.”

The expert advised patients using any recalled products to consult their ophthalmologist before making changes to their treatment plans.

(The above story first appeared on LatestLY on Aug 02, 2026 12:26 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).